Focus: Quadriga BioSciences is an early-stage oncology biotech focused on first-in-class chemotherapeutic agents, headquartered in Los Altos, CA. The company is pre-revenue with a pipeline targeting difficult-to-treat cancers including brain metastases, glioblastoma, and breast cancer.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Quadriga offers early-stage oncology upside but carries pre-revenue risk; suitable only for risk-tolerant candidates seeking scientific depth over immediate stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Quadriga BioSciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Quadriga BioSciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles